Focusing on neuroblastoma, researchers from the Perelman School of Medicine and Children’s Hospital of Philadelphia have harnessed the immune system to destroy tumors. In a major step forward for the treatment of aggressive solid cancers, researchers from Penn’s Perelman School of Medicine and the Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside...
by Georgia Institute of Technology Credit: CC0 Public Domain A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers. CAR...
UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE PHILADELPHIA–When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn’t respond, they went back to the drawing board to determine why. They discovered that less is more when it comes to the...
by Perelman School of Medicine at the University of Pennsylvania Credit: CC0 Public Domain The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors. Now, in a new study published online today in Nature Cancer, Penn Medicine researchers found that combining chimeric antigen receptor...
CD-19-targeting CAR-T cells restored proper skin structure and reduced inflammation in mouse models of lupus (bottom). Credit: R. Kansal et al., Science Translational Medicine (2019) Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded...
